Tirabrutinib

Name: Tirabrutinib in Primary central nervous system lymphoma: Effects of Tirabrutinib on other drugs
Published: 2026-09-14T15:39:06-04:00

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Drug/Drug, drug/disease interactions

Effects of Tirabrutinib on other drugs

2 evidence topics · 2 sources

In vitro CYP and transporter inhibition

“In vitro data indicate tirabrutinib has the potential to inhibit several CYPs and transporters.” (opens the source at this quote in a new tab)

In vitro anthracycline interactions

“Our in vitro data demonstrate that tirabrutinib influences daunorubicin pharmacodynamics by targeting both metabolic and transport pathways.” (opens the source at this quote in a new tab)